HDR brachytherapy as a single-day monotherapy: Survival results of a phase II randomized trial

被引：0
|
作者：
Jolicoeur, M. [1 ]
Derashodian, T. [1 ]
Nguyen-Huynh, T.
Hillmann, E. [1 ]
Denis, T. [1 ]
Heliou, R. [1 ]
机构：
[1] Hop Charles LeMoyne, Radiat Oncol, Greenfield Pk, PQ, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2021年 / 158卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OC-0102
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [41] A PROSPECTIVE RANDOMIZED TRIAL COMPARING HDR-BRACHYTHERAPY AND TRANSARTERIAL CHEMOEMBOLIZATION IN HEPATOCELLULAR CARCINOMA
    Mohnike, K.
    Pech, M.
    Seidensticker, M.
    Seidensticker, R.
    Bretschneider, T.
    Schuette, K.
    Schulz, C.
    Malfertheiner, P.
    Ricke, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S50 - S50
  • [42] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Zhang, Liying
    Ravi, Ananth
    D'Alimonte, Laura
    Loblaw, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [43] MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial
    Alayed, Yasir
    D'Alimonte, Laura
    Helou, Joelle
    Ravi, Ananth
    Morton, Gerard
    Chung, Hans T.
    Haider, Masoom
    McGuffin, Merrylee
    Zhang, Liying
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2019, 141 : 144 - 148
  • [44] Phase I/II trial of HDR-brachytherapy boosted comprehensive IMRT for intermediate-risk adenocarcinoma of the prostate
    Hagan, M.
    Todor, D.
    Dogan, N.
    Wu, Y.
    Anscher, M.
    Arthur, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S363 - S363
  • [45] HIGH-DOSE-RATE BRACHYTHERAPY AS A MONOTHERAPY FOR FAVORABLE-RISK PROSTATE CANCER: A PHASE II TRIAL
    Barkati, Maroie
    Williams, Scott G.
    Foroudi, Farshad
    Tai, Keen Hun
    Chander, Sarat
    van Dyk, Sylvia
    See, Andrew
    Duchesne, Gillian M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05): : 1889 - 1896
  • [46] High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial
    Yoshioka, Y
    Nose, T
    Yoshida, K
    Inoue, T
    Yamazaki, H
    Tanaka, E
    Shiomi, H
    Imai, A
    Nakamura, S
    Shimamoto, S
    Inoue, T
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03): : 675 - 681
  • [47] Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer
    Vigneault, E.
    Morton, G.
    Perulekar, W.
    Niazi, T.
    Springer, G.
    Barkati, M.
    Chung, P.
    Koll, W.
    Kamran, A.
    Montreal, M.
    Ding, K.
    Loblaw, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S975 - S976
  • [48] Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III trial
    Celio, L.
    Bajetta, E.
    Denaro, A.
    Bichisao, E.
    Frustaci, S.
    Ardizzoia, A.
    Piazza, E.
    Fabi, A.
    Capobianco, A.
    Isa, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Single-day and multiday repeatability of stance analysis results for dogs with hind limb lameness
    Wilson, Megan L.
    Roush, James K.
    Renberg, Walter C.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2019, 80 (04) : 403 - 409
  • [50] Oral isotretinoin for photoaging: Results of a randomized controlled phase II trial
    Bagatin, Edileia
    Miot, Helio
    Parada, Meire
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB23 - AB23
12345